Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Mesoblast ( (MESO) ) has shared an update.
Mesoblast Limited has announced a significant change in the holdings of its director, Dr. Eric Rose. On December 13, 2024, Dr. Rose acquired 5,039,814 ordinary shares through a share placement approved by shareholders at the 2024 AGM, increasing his total holdings to 5,451,434 ordinary shares. This acquisition reflects the company’s ongoing strategic maneuvers to strengthen its leadership position and potentially enhance shareholder value.
More about Mesoblast
Mesoblast Limited is a company in the biotechnology sector focused on regenerative medicine, particularly the development of cellular therapies for inflammatory diseases, orthopedics, and cardiovascular conditions. The company leverages its proprietary mesenchymal lineage cell therapy technology to address unmet medical needs.
YTD Price Performance: 565.00%
Average Trading Volume: 322,381
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.74B
For detailed information about MESO stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Top Investor About Trump Media Stock
- Will Shari Redstone’s Relationship With Trump Save Paramount (NASDAQ:PARA) Merger?
- Ford (NYSE:F) Offers Free Cars to Trump Inauguration
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
